308 related articles for article (PubMed ID: 20059760)
1. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
Schrezenmeier H; Seifried E
Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
[TBL] [Abstract][Full Text] [Related]
2. The ethics of wasting the donor's gift of buffy coat.
Vamvakas EC
Vox Sang; 2011 Feb; 100(2):256-7; author reply 258-9. PubMed ID: 20825600
[No Abstract] [Full Text] [Related]
3. Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply.
Zimmermann R; Blasczyk R; Zingsem J; Eckstein R; Heuft HG
Vox Sang; 2010 Oct; 99(3):295-6; author reply 297-8. PubMed ID: 20561324
[No Abstract] [Full Text] [Related]
4. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
Lozano ML; Rivera J; Vicente V
Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
[TBL] [Abstract][Full Text] [Related]
5. A critical comparison of platelet preparation methods.
Vassallo RR; Murphy S
Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
[TBL] [Abstract][Full Text] [Related]
6. Preparation, storage and quality control of platelet concentrates.
Tynngård N
Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
[TBL] [Abstract][Full Text] [Related]
7. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
8. Platelet concentrates, from whole blood or collected by apheresis?
van der Meer PF
Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
[TBL] [Abstract][Full Text] [Related]
9. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
Riggert J; Humpe A; Simson G; Köhler M
Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646
[TBL] [Abstract][Full Text] [Related]
10. Use of random versus apheresis platelet concentrates.
Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
[TBL] [Abstract][Full Text] [Related]
11. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
Ali SF
Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
[TBL] [Abstract][Full Text] [Related]
12. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
[TBL] [Abstract][Full Text] [Related]
13. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
Singh S; Shams Hakimi C; Jeppsson A; Hesse C
Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
[TBL] [Abstract][Full Text] [Related]
14. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
[TBL] [Abstract][Full Text] [Related]
16. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ
Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711
[TBL] [Abstract][Full Text] [Related]
17. Preparation and storage of white blood cell-reduced split apheresis platelet concentrates for pediatric use.
van der Meer PF; Vrielink H; Pietersz RN
Transfusion; 2005 Feb; 45(2):223-7. PubMed ID: 15660831
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Impact-R for monitoring the platelet storage lesion.
Albanyan AM; Murphy MF; Harrison P
Platelets; 2009 Feb; 20(1):1-6. PubMed ID: 19172514
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cytokine accumulation in platelets obtained with the COBE spectra apheresis system.
Palmer DS; Aye MT; Dumont L; Dumont D; McCombie N; Giulivi A; Rutherford B; Trudel E; Hashemi-Tavoularis S
Vox Sang; 1998; 75(2):115-23. PubMed ID: 9784664
[TBL] [Abstract][Full Text] [Related]
20. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
